GO:0004622 phosphatidylcholine lysophospholipase A1 activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0004622 describes the hydrolysis of 1-acyl-sn-glycero-3-phosphocholine to a fatty acid, H+, and sn-glycerol 3-phosphocholine, a key step in lysophosphatidylcholine (LPC) catabolism.
• The reaction is catalyzed by lysophospholipases, including phospholipase B and lysophospholipase A1-type enzymes, which remove the remaining acyl chain from LPC.
• LPC, the substrate of this activity, is a bioactive lipid linked to inflammation, atherosclerosis, cancer, and neurological disorders.
• Enzymes with this activity contribute to the glycerophosphodiester pathway, producing sn-glycerol 3-phosphocholine for further metabolism.
• Dysregulation of LPC metabolism, including lysophospholipase activity, is implicated in pancreatic cancer progression and chronic lymphocytic leukemia.
• CRISPR-based knockout, point mutation, and overexpression models enable precise dissection of genes encoding phosphatidylcholine lysophospholipase A1 activity in disease contexts.
Description
Phosphatidylcholine lysophospholipase A1 activity (GO:0004622) is a molecular function that catalyzes the hydrolysis of 1-acyl-sn-glycero-3-phosphocholine (lysophosphatidylcholine, LPC) into a free fatty acid, a proton, and sn-glycerol 3-phosphocholine. This activity is central to the deacylation of phosphatidylcholine and the turnover of lysophospholipids, which are potent signaling molecules. LPC is generated by phospholipase A2 and can be further metabolized by lysophospholipases, including enzymes with phospholipase B or lysophospholipase A1 activity. The reaction is conserved across species, from bacteria and fungi to mammals, and is important for membrane remodeling and lipid homeostasis. Researchers study GO:0004622 because LPC accumulation is associated with a range of pathological conditions, including inflammation, atherosclerosis, cancer, and neurodegenerative diseases. For example, stromal lysolipid-autotaxin signaling involving LPC promotes pancreatic tumor progression, and ENPP2 (autotaxin) drives lipid accumulation in chronic lymphocytic leukemia. The enzyme activities that degrade LPC, such as phosphatidylcholine lysophospholipase A1, therefore represent potential therapeutic targets. Understanding the catalytic mechanism, substrate specificity, and regulation of these enzymes is essential for developing modulators. This article provides a comprehensive overview of GO:0004622, covering its definition, biological significance, key genes, regulatory mechanisms, disease associations, and experimental approaches including CRISPR-based models. All statements are supported by published literature.
phosphatidylcholine lysophospholipase A1 activity At A Glance
| GO ID | GO:0004622 |
|---|---|
| GO term | phosphatidylcholine lysophospholipase A1 activity |
| Ontology | molecular_function |
| Synonym | lysophospholipase activity; lecithinase B activity; phospholipase B activity; lysolecithinase activity; lysophosphatidylcholine hydrolase activity |
| Major function | Hydrolysis of lysophosphatidylcholine to fatty acid and sn-glycerol 3-phosphocholine |
| Substrate | 1-acyl-sn-glycero-3-phosphocholine (lysophosphatidylcholine) |
| Products | Fatty acid, H+, sn-glycerol 3-phosphocholine |
| Reaction direction | Irreversible hydrolysis |
| Cellular location | Membrane-associated, often extracellular or lysosomal (based on enzyme context) |
What Is GO:0004622?
Phosphatidylcholine lysophospholipase A1 activity is defined as the catalysis of the reaction: a 1-acyl-sn-glycero-3-phosphocholine + H2O = a fatty acid + H+ + sn-glycerol 3-phosphocholine. In simpler terms, it is an enzymatic activity that removes the remaining fatty acid from lysophosphatidylcholine, releasing a free fatty acid and glycerophosphocholine. This activity is also known by synonyms such as lysophospholipase activity, lecithinase B, and phospholipase B activity.
Why Is phosphatidylcholine lysophospholipase A1 activity Important in Cell Biology?
GO:0004622 is important because it controls the levels of lysophosphatidylcholine (LPC), a bioactive lipid that modulates inflammation, cell proliferation, and membrane integrity. By degrading LPC, enzymes with this activity prevent its accumulation and the resulting pathological signaling. LPC is a major component of oxidized LDL and a chemoattractant for monocytes, linking this activity to atherosclerosis. In cancer, LPC can be converted by autotaxin (ENPP2) to lysophosphatidic acid (LPA), a potent promoter of tumor progression and metastasis. Therefore, phosphatidylcholine lysophospholipase A1 activity indirectly regulates LPA production by limiting substrate availability. Additionally, the reaction product sn-glycerol 3-phosphocholine is an osmolyte and a precursor for phospholipid synthesis. Understanding this activity is crucial for developing therapies targeting lipid metabolism in cancer, inflammation, and metabolic disorders.
• Regulates lysophosphatidylcholine (LPC) levels, preventing its pro-inflammatory and cytotoxic effects.
• Controls the availability of LPC for autotaxin (ENPP2)-mediated production of lysophosphatidic acid (LPA), a key oncogenic lipid.
• Contributes to membrane phospholipid remodeling and turnover.
• Produces sn-glycerol 3-phosphocholine, which can be further metabolized to glycerol-3-phosphate for lipid synthesis.
• Dysregulation is linked to pancreatic cancer progression via stromal lysolipid signaling.
• Implicated in chronic lymphocytic leukemia through ENPP2-mediated lipid accumulation.
• Potential role in skin barrier function and epidermal lipid metabolism.
• Fungal phospholipase B with this activity is a model for studying enzyme mechanism and inhibitor design.
• Alternative splicing can generate enzymes with lysophospholipase activity, expanding functional diversity.
• Provides a target for anti-inflammatory and anti-cancer drug discovery.
What Happens During phosphatidylcholine lysophospholipase A1 activity?
Substrate recognition and binding
In simple terms: The enzyme grabs a lysophosphatidylcholine molecule from the membrane.
The enzyme binds to 1-acyl-sn-glycero-3-phosphocholine (LPC), positioning the sn-1 ester bond for hydrolysis. This step often occurs at membrane interfaces, where the enzyme accesses its substrate. The binding specificity is determined by the enzyme's active site, which accommodates the choline headgroup and the single acyl chain of LPC.
Catalytic hydrolysis
In simple terms: Water breaks the bond between the fatty acid and the rest of the molecule.
A water molecule attacks the ester carbonyl, leading to the cleavage of the acyl chain and release of a free fatty acid and sn-glycerol 3-phosphocholine. This hydrolysis is catalyzed by a serine hydrolase-like mechanism in many lysophospholipases, involving a catalytic triad. The reaction is essentially irreversible under physiological conditions.
Product release and recycling
In simple terms: The products are released and can be used elsewhere.
The fatty acid and sn-glycerol 3-phosphocholine are released from the active site. sn-Glycerol 3-phosphocholine can be further degraded by glycerophosphodiesterases to glycerol-3-phosphate and choline, entering phospholipid synthesis or energy metabolism. The fatty acid may be re-esterified into phospholipids or used for signaling.
Role in LPC metabolism and signaling
In simple terms: This activity controls how much LPC is available for signaling.
By degrading LPC, phosphatidylcholine lysophospholipase A1 activity directly opposes the production of LPC by phospholipase A2. This balance is critical because LPC can be converted by autotaxin (ENPP2) to lysophosphatidic acid (LPA), a potent mitogen and motility factor. Thus, this activity indirectly modulates LPA-driven processes such as cancer cell proliferation and migration.
Key Genes Involved in GO:0004622 phosphatidylcholine lysophospholipase A1 activity
The following genes encode enzymes that exhibit phosphatidylcholine lysophospholipase A1 activity or are closely related to its function, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PLA2G15 | Lysophospholipase A1/A2 with broad substrate specificity | Linked to lysosomal phospholipid degradation and drug-induced phospholipidosis |
| PNPLA6 | Neuropathy target esterase, phospholipase B-like | Mutations cause motor neuron disease; involved in phosphatidylcholine deacylation |
| PNPLA7 | Lysophospholipase with preference for LPC | Regulates LPC levels in liver and adipose tissue; linked to metabolic disease |
| ABHD12 | Lysophosphatidylserine lipase, also acts on LPC | Mutations cause PHARC syndrome; role in neuroinflammation |
| ABHD6 | Lysophospholipase and monoacylglycerol lipase | Regulates endocannabinoid and lysophospholipid signaling |
| LYPLA1 | Lysophospholipase 1, acyl-protein thioesterase | Depalmitoylates proteins; also has lysophospholipase activity |
| LYPLA2 | Lysophospholipase 2 | Involved in protein depalmitoylation and lipid metabolism |
| ENPP2 | Autotaxin, lysophospholipase D | Produces LPA from LPC; promotes cancer progression |
| PLA2G7 | Lipoprotein-associated phospholipase A2 | Hydrolyzes oxidized phospholipids; also has lysophospholipase activity |
| PLA2G4A | Cytosolic phospholipase A2 | Generates LPC from phosphatidylcholine; upstream of lysophospholipases |
| PLA2G2A | Secretory phospholipase A2 | Produces LPC; associated with inflammation and cancer |
| LPCAT1 | Lysophosphatidylcholine acyltransferase 1 | Re-acylates LPC to phosphatidylcholine; opposes lysophospholipase activity |
| LPCAT2 | Lysophosphatidylcholine acyltransferase 2 | Similar to LPCAT1; involved in inflammatory responses |
| GDE1 | Glycerophosphodiester phosphodiesterase 1 | Degrades sn-glycerol 3-phosphocholine produced by GO:0004622 |
| GDPD5 | Glycerophosphodiester phosphodiesterase 5 | Metabolizes glycerophosphocholine; linked to osmoregulation |
| PLB1 | Phospholipase B1 | Fungal and mammalian phospholipase B with lysophospholipase activity |
| PSPLA1 | Phosphatidylserine-specific phospholipase A1 | Alternative splicing yields lysophospholipase activity |
How Is phosphatidylcholine lysophospholipase A1 activity Regulated?
The activity of enzymes with phosphatidylcholine lysophospholipase A1 function is regulated at multiple levels. Transcriptional regulation controls enzyme abundance in response to inflammatory stimuli and lipid status. Post-translational modifications, such as phosphorylation and palmitoylation, can modulate catalytic activity and subcellular localization. For example, autotaxin (ENPP2) secretion and activity are regulated by the AMPK/SREBP1/FAS pathway in chronic lymphocytic leukemia. Additionally, the availability of substrate LPC, which is produced by phospholipase A2 enzymes, directly influences flux through this activity. Competitive inhibition by other lysophospholipids and feedback from product accumulation may also play a role.
phosphatidylcholine lysophospholipase A1 activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ENPP2 | Pancreatic cancer, chronic lymphocytic leukemia | Knockout or overexpression in cancer cell lines; xenograft models |
| PNPLA6 | Motor neuron disease, neurodegeneration | Point mutation knock-in in mice; neuronal cell models |
| ABHD12 | PHARC syndrome, neuroinflammation | Knockout mice; iPSC-derived neurons |
| PLA2G7 | Atherosclerosis, cardiovascular disease | Knockout in ApoE-/- mice; macrophage models |
| LPCAT1 | Cancer, inflammation | Overexpression in cancer cell lines; knockout in mice |
Cancer and tumor progression
Lysophosphatidylcholine (LPC) metabolism is reprogrammed in many cancers. Stromal lysolipid-autotaxin signaling promotes pancreatic tumor progression, where LPC is converted to lysophosphatidic acid (LPA) by ENPP2. In chronic lymphocytic leukemia, ENPP2 promotes progression and lipid accumulation via the AMPK/SREBP1/FAS pathway. Phosphatidylcholine lysophospholipase A1 activity, by degrading LPC, can limit LPA production and thus may suppress tumor growth. However, the role of specific lysophospholipases in cancer is context-dependent and requires further study.
Inflammation and atherosclerosis
LPC is a pro-inflammatory mediator that attracts monocytes and induces cytokine production. It is a major component of oxidized LDL and contributes to atherosclerosis. Enzymes with phosphatidylcholine lysophospholipase A1 activity degrade LPC, potentially reducing inflammation. Conversely, excessive activity could produce fatty acids that fuel inflammatory pathways. The balance between LPC production and degradation is critical in cardiovascular disease.
Neurological disorders
LPC is a component of myelin and can cause demyelination when injected into nerves. Dysregulation of LPC metabolism has been implicated in multiple sclerosis and other neurodegenerative conditions. Mutations in PNPLA6, which has phospholipase B activity, cause motor neuron disease, highlighting the importance of lysophospholipid metabolism in the nervous system. ABHD12 mutations cause PHARC syndrome, a neurodegenerative disorder, further linking lysophospholipase activity to neuronal health.
Metabolic and skin disorders
Phospholipase A and lysophospholipase activities have been detected in the epidermis, suggesting a role in skin barrier function and lipid metabolism. In metabolic disorders, altered LPC levels are associated with insulin resistance and obesity. The glycerophosphodiester product sn-glycerol 3-phosphocholine is an osmolyte, and its metabolism is linked to cellular stress responses.
From phosphatidylcholine lysophospholipase A1 activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a candidate lysophospholipase alter LPC levels? | CRISPR knockout in HEK293 or HeLa cells followed by lipidomics |
| Does a specific point mutation affect catalytic activity? | CRISPR point mutation knock-in of catalytic residues, e.g., serine to alanine |
| Does overexpression of the enzyme reduce LPC-induced inflammation? | CRISPR knock-in of a tet-inducible promoter or lentiviral overexpression |
| Where is the enzyme localized in the cell? | CRISPR knock-in of a fluorescent tag (e.g., GFP) at the endogenous locus |
| Does the enzyme regulate LPA production in cancer? | Knockout in cancer cell lines co-cultured with stromal cells, measure LPA |
| Can a candidate gene rescue a knockout phenotype? | CRISPR knock-in of wild-type or mutant cDNA into a safe harbor locus |
How to Study the phosphatidylcholine lysophospholipase A1 activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| LC-MS lipidomics | LPC, fatty acid, and glycerophosphocholine levels | Quantify changes in lipid metabolism after gene knockout |
| Fluorescent enzyme assay | Lysophospholipase activity in vitro | Screen for inhibitors or characterize mutants |
| CRISPR knockout screen | Genes affecting LPC sensitivity or metabolism | Identify novel regulators of lysophospholipid homeostasis |
| RNA-seq | Transcriptional changes upon enzyme perturbation | Discover pathways co-regulated with lysophospholipases |
| Proximity labeling (BioID) | Protein interactors of lysophospholipases | Map regulatory complexes |
| Live-cell imaging | Subcellular localization and dynamics | Track enzyme recruitment to membranes |
| Phospholipid profiling by TLC | Separation of lipid classes | Confirm enzyme activity in vitro |
| Site-directed mutagenesis | Catalytic residues essential for activity | Validate mechanism and design point mutations |
Lipidomics and enzyme assays
Mass spectrometry-based lipidomics is the primary method to measure LPC and its metabolites. Enzyme activity can be assayed using fluorescent or radioactive substrates, such as 1-acyl-sn-glycero-3-phosphocholine labeled with a fluorophore. These methods quantify the release of fatty acid or sn-glycerol 3-phosphocholine.
CRISPR screening and functional genomics
Genome-wide CRISPR knockout screens can identify genes required for LPC metabolism or resistance to LPC-induced toxicity. Pooled screens with next-generation sequencing readouts enable unbiased discovery of lysophospholipase regulators.
Proteomics and interactomics
Affinity purification coupled with mass spectrometry can identify protein-protein interactions of lysophospholipases. Proximity labeling (BioID) can map the interactome in living cells, revealing regulatory partners.
Imaging and subcellular localization
Fluorescence microscopy of tagged enzymes (e.g., GFP knock-in) reveals subcellular localization. Live-cell imaging with lipid biosensors can track LPC dynamics in real time.
How CRISPR Can Be Used to Study GO:0004622 phosphatidylcholine lysophospholipase A1 activity
Knockout
CRISPR knockout of genes encoding phosphatidylcholine lysophospholipase A1 activity, such as PNPLA6 or ABHD12, can be achieved by introducing frameshift mutations in early exons. These models are used to study the consequences of loss of enzyme activity on LPC accumulation, cellular signaling, and disease phenotypes. For example, knockout of ENPP2 in cancer cells reduces LPA production and tumor progression.
Point Mutation
CRISPR point mutation knock-in can introduce specific amino acid substitutions in catalytic residues (e.g., serine to alanine) to abolish enzymatic activity without affecting protein expression. This approach distinguishes catalytic activity from scaffolding functions. It is particularly useful for enzymes with multiple domains.
Knock-in
CRISPR knock-in can be used to insert tags (e.g., GFP, HA) or inducible promoters at the endogenous locus. Tagged knock-in allows visualization and immunoprecipitation of the enzyme at physiological levels. Knock-in of disease-associated mutations (e.g., PNPLA6 mutations) creates isogenic models for studying pathogenesis.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression can drive high-level expression of lysophospholipases to study gain-of-function effects. Overexpression models are useful for identifying downstream signaling changes and for drug screening. However, careful controls are needed to avoid artifacts from supraphysiological expression.
How EDITGENE Supports phosphatidylcholine lysophospholipase A1 activity Research
Researchers studying phosphatidylcholine lysophospholipase A1 activity-related genes often need to determine whether a candidate gene is causally involved in lipid metabolism, disease progression, or drug response. EDITGENE provides a comprehensive suite of CRISPR-based services to enable precise genetic manipulation and functional interrogation of these genes.
Contact EDITGENE today to design your custom CRISPR model for phosphatidylcholine lysophospholipase A1 activity research.
Frequently Asked Questions About phosphatidylcholine lysophospholipase A1 activity
What is phosphatidylcholine lysophospholipase A1 activity?
It is an enzymatic activity (GO:0004622) that hydrolyzes lysophosphatidylcholine into a free fatty acid, a proton, and sn-glycerol 3-phosphocholine.
What genes are involved in phosphatidylcholine lysophospholipase A1 activity?
Genes such as PNPLA6, PNPLA7, ABHD12, LYPLA1, LYPLA2, and ENPP2 encode enzymes with this activity or related lysophospholipase functions.
What diseases are associated with lysophospholipase A1 activity?
Dysregulation is linked to cancer (pancreatic, leukemia), atherosclerosis, neurodegenerative disorders, and metabolic diseases.
How is phosphatidylcholine lysophospholipase A1 activity measured?
It is measured using enzyme assays with fluorescent or radioactive substrates, or by mass spectrometry-based lipidomics.
What is the difference between phospholipase A1 and lysophospholipase A1?
Phospholipase A1 removes a fatty acid from phosphatidylcholine, while lysophospholipase A1 removes the remaining fatty acid from lysophosphatidylcholine.
Can CRISPR be used to study phosphatidylcholine lysophospholipase A1 activity?
Yes, CRISPR knockout, point mutation, and knock-in models enable precise manipulation of genes encoding this activity.
What is the role of ENPP2 in lysophospholipid metabolism?
ENPP2 (autotaxin) has lysophospholipase D activity, converting LPC to lysophosphatidic acid (LPA), and is involved in cancer progression.
Which tissues express enzymes with this activity?
They are expressed in many tissues, including liver, brain, skin, and immune cells, reflecting their broad role in lipid metabolism.
What are the products of phosphatidylcholine lysophospholipase A1 activity?
The products are a fatty acid, a proton (H+), and sn-glycerol 3-phosphocholine.
How does this activity relate to inflammation?
By degrading LPC, a pro-inflammatory lipid, this activity can reduce inflammation, but excessive fatty acid release may also promote inflammatory signaling.
Conclusion
Phosphatidylcholine lysophospholipase A1 activity (GO:0004622) is a fundamental enzymatic function that controls lysophosphatidylcholine levels and thereby influences lipid signaling, membrane homeostasis, and disease progression. Its roles in cancer, inflammation, and neurodegeneration make it an attractive target for therapeutic intervention. Advances in CRISPR-based models and lipidomics are accelerating our understanding of the enzymes that carry out this activity. EDITGENE offers comprehensive services to support research on these genes, from knockout to knock-in and screening.
References
- 1. Law SH et al.. 2019. An Updated Review of Lysophosphatidylcholine Metabolism in Human Diseases.. Int J Mol Sci 20(5) PMID: 30845751
- 2. Auciello FR et al.. 2019. A Stromal Lysolipid-Autotaxin Signaling Axis Promotes Pancreatic Tumor Progression.. Cancer Discov 9(5):617-627 PMID: 30837243
- 4. Lu L et al.. 2024. ENPP2 promotes progression and lipid accumulation via AMPK/SREBP1/FAS pathway in chronic lymphocytic leukemia.. Cell Mol Biol Lett 29(1):159 PMID: 39731014
- 5. Patton-Vogt J. 2007. Transport and metabolism of glycerophosphodiesters produced through phospholipid deacylation.. Biochim Biophys Acta 1771(3):337-42 PMID: 16781190
- 6. Long VJ. 1975. Phospholipase A and lysophospholipase activity of the epidermis.. Br J Dermatol 92(6):603-10 PMID: 241370
- 7. Saito K. 2014. Reminiscence of phospholipase B in Penicillium notatum.. Proc Jpn Acad Ser B Phys Biol Sci 90(9):333-46 PMID: 25391318
- 8. Nagai Y et al.. 1999. An alternative splicing form of phosphatidylserine-specific phospholipase A1 that exhibits lysophosphatidylserine-specific lysophospholipase activity in humans.. J Biol Chem 274(16):11053-9 PMID: 10196188
